Sangamo rises after trial data for Fabry disease therapy
Source: SeekingAlpha
2025-06-24 08:46:36 ET
More on Sangamo Therapeutics
- Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript
- Sangamo Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation
- Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal
- RFK Jr. looks to fast track rare disease drug approvals (updated)
- Sangamo Therapeutics prices $23M securities offering
Read the full article on Seeking Alpha
For further details see:
Sangamo rises after trial data for Fabry disease therapy
Amicus Therapeutics Inc.
NASDAQ: FOLD
FOLD Trading
0.0% G/L:
$14.375 Last:
1,009,393 Volume:
$14.37 Open:
FOLD Latest News
February 20, 2026 04:01:00 pm
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
FOLD Stock Data
$4,416,657,740
301,745,810
0.4%
110
N/A
Biotechnology & Life Sciences
Healthcare
US
Princeton
